Morepen Laboratories Ltd. (BSE: 500288) is a Gurugram, Haryana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹5,206 Cr, it ranks #822 by market cap among the 6,197 Indian listed companies on FinBizNet, and #23 of 86 in Medicinal Chemicals and Botanical Products. At ₹99.64 (as of 16 Nov 2026), the share price is 33.9% below its 52-week high of ₹150.70 and 195.8% above its 52-week low of ₹33.68. The share price is up 112.1% over one year and up 23.2% over three months.
| Current Price | ₹99.64 |
|---|---|
| Market Cap | ₹5,206 Cr |
| BSE Code | 500288 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 55.1 |
| Return on Equity | 7.80% |
| Return on Assets | 3.00% |
| 52-Week Range | ₹33.68 – ₹150.70 |
| 1-Year Price Change | +112.1% |
| 3-Month Price Change | +23.2% |
| Beta (1Y) | 0.93 |
| Dividend Yield | 0.21% |
| Headquarters | Gurugram, Haryana |
| Website | www.morepen.com |
| Revenue | ₹747 Cr |
|---|---|
| Net Profit | ₹89 Cr |
| Net Margin | 11.9% |
| EPS (Basic) | ₹1.62 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Morepen Laboratories Ltd. reported revenue of ₹747 Cr in Q2 FY27, up 81.4% from ₹412 Cr in Q2 FY26 and up 30.9% from ₹570 Cr in Q1 FY27. It posted a net profit of ₹89 Cr for the quarter, against a net profit of ₹41 Cr in Q2 FY26 (up 117.5%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹412 Cr (Q2 FY26) to ₹747 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹747 Cr | ₹89 Cr | 11.9% |
| Q1 FY27 | ₹570 Cr | ₹56 Cr | 9.9% |
| Q4 FY26 | ₹485 Cr | ₹16 Cr | 3.2% |
| Q3 FY26 | ₹484 Cr | ₹28 Cr | 5.7% |
| Q2 FY26 | ₹412 Cr | ₹41 Cr | 9.9% |
| Q1 FY26 | ₹425 Cr | ₹11 Cr | 2.5% |
| Q4 FY25 | ₹466 Cr | ₹20 Cr | 4.4% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 35.65% of Morepen Laboratories Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 100.0% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, a first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, di
1. Pharmaceutical Business-This segment manufactures and sells active pharmaceutical ingredients (APIs), formulations, and home health products.
1. Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Morepen Laboratories Ltd. | ₹5,206 Cr | 55.1 | 7.80% | ₹747 Cr | +112.1% |
Listed by market capitalisation. Ratios are shown for context only.
Morepen Laboratories Ltd. is trading at ₹99.64, with a market capitalisation of ₹5,206 Cr.
Morepen Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Morepen Laboratories Ltd. has a P/E of 55.1 and a return on equity of 7.80%.
Morepen Laboratories Ltd. is listed on the BSE under the scrip code 500288.
Morepen Laboratories Ltd.'s share price is up 112.1% over one year and up 23.2% over three months. Its 52-week range is ₹33.68 to ₹150.70.
In Q2 FY27, Morepen Laboratories Ltd. reported revenue of ₹747 Cr and net profit of ₹89 Cr, with basic EPS of ₹1.62 (consolidated, parsed from the company's exchange filing).
Morepen Laboratories Ltd. reported revenue of ₹747 Cr in Q2 FY27, up 81.4% from ₹412 Cr in Q2 FY26 and up 30.9% from ₹570 Cr in Q1 FY27.
Promoters held 35.65% of Morepen Laboratories Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.